Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
Gilead Sciences(GILD) stock is priced at $138.99, giving the company a market capitalization of 172.57B. It carries a P/E multiple of 20.95 and pays a dividend yield of 2.2%.
During the trading session on 2026-04-11, Gilead Sciences(GILD) shares reached a daily high of $143.06 and a low of $138.45. At a current price of $138.99, the stock is +0.4% higher than the low and still -2.8% under the high.
Trading activity shows a volume of 4.29M, compared to an average daily volume of 5.28M.
The stock's 52-week range extends from a low of $93.37 to a high of $157.29.
The stock's 52-week range extends from a low of $93.37 to a high of $157.29.
GILD News
Early 2026, Gilead Sciences (NasdaqGS:GILD) has moved quickly on acquisitions of Arcellx, Ouro Medicines, and Tubulis. The company has also exercised exclusive...
The company broadened its multi-year collaboration with Tempus to enhance oncology research and development. At the same time, it exercised an option to licens...
Tempus AI (TEM) announced an expanded, multi-year collaboration with Gilead Sciences (GILD) aimed at building and advancing Gilead’s oncology pipeline. To date,...
Analyst ratings
75%
of 32 ratingsMore GILD News
(RTTNews) - Healthcare technology company Tempus AI, Inc. (TEM) Thursday announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (GILD) to bu...
Kymera Therapeutics (KYMR) announced that Gilead Sciences (GILD) has exercised its option to exclusively license KT-200, oral CDK2 molecular glue degrader devel...
Truist analyst Gregory Renza raised the firm’s price target on Gilead (GILD) to $155 from $152 and keeps a Buy rating on the shares as part of a broader researc...
Gilead Sciences, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan Seigerman from BMO Capital maintained a Buy ratin...
Gilead (GILD) said on Tuesday that it would acquire Germany-based biotechnology firm Tubulis GmbH for $5B to build on its oncology pipeline. The acquisition wi...
Gilead said it plans to fund the acquisition, slated to close in the second quarter, with cash on hand and senior unsecured notes. Mike Blake/REUTERS Gilead Sc...
(RTTNews) - Gilead Sciences, Inc. (GILD) announced Tuesday it has entered into a definitive agreement to acquire German biotechnology company Tubulis GmbH to bu...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.